Nachrichten zur Bristol-Myers Squibb Co. Aktie

Why were lowering our Bristol Myers price target despite an earnings beat, guidance raise

Shares of Bristol Myers Squibb fell modestly after the drugmakers better-than-expected first-quarter results.…

Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trumps planned…

Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales

Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio…

AKTIE IM FOKUS: Evotec-Erholung stockt trotz Erfolgs in Forschungsallianz

FRANKFURT (dpa-AFX) - Die Aktien von Evotec sind am Donnerstag zunächst an ihre charttechnischen Grenzen gestoßen. Erfolge in einer…

EVOTEC-Aktie deutlich höher: Erfolgszahlungen von Bristol Myers Squibb

Diese belaufen sich auf 75 Millionen US-Dollar. Leistungs- und programmabhängige Erfolge hätten die Zahlungen ausgelöst, teilte EVOTEC in Hamburg mit.…

EQS-News: Evotec verkündet starke Fortschritte in strategischer Kollaboration mit Bristol Myers Squibb im Bereich Protein Degradation (deutsch)

Evotec verkündet starke Fortschritte in strategischer Kollaboration mit Bristol Myers Squibb im Bereich Protein Degradation^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec…

Bristol-Myers Squibb Aktie: Zitterpartie vor Quartalszahlen

Pharmariese Bristol-Myers Squibb kämpft mit Studienflop und sinkendem Aktienkurs. Analysten bleiben gespalten vor den Q1-Zahlen. Die Aktie des Pharmariesen Bristol-Myers…

Stocks making the biggest moves after hours: Tesla, Enphase Energy, Oklo, Bristol Myers Squibb and more

These are the stocks posting the largest moves in extended trading.…

Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession

…

Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Weeks Release

Bristol Myers (BMY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Bristol Myers Squibb (BMY) Stock Moves -1.35%: What You Should Know

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $49.33, indicating a -1.35% shift from the previous…

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill?

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors…

Bristol-Myers Squibb muss einen herben Studienrückschlag verkraften

Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Bristol-Myers Squibb Company…

Bristol Myers Squibb: Bittere Pille

Der US-amerikanische Pharma-Konzern Bristol Myers Squibb muss einen herben Studienrückschlag verkraften. Die Substanz Mavacamten, die sich das Unternehmen durch die…

Bristol-Myers Squibb Aktie: Ringen um Klarheit?

Der US-Pharmariese verzeichnet eine minimale Kursstabilisierung nach dramatischen Verlusten, während UBS ihr Kursziel senkt und Analysten zunehmend skeptisch bleiben. Die…

Heres Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $53.78, denoting a +1.34% change from…

Is Vertex Pharmaceuticals Stock a Buy?

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex…

The Zacks Analyst Blog Highlights Exxon Mobil, Bristol-Myers Squibb, Chubb and Hamilton Beach Brands

Exxon Mobil, Bristol-Myers Squibb, Chubb and Hamilton Beach Brands are part of the Zacks top Analyst Blog.…

Top Research Reports for Exxon Mobil, Bristol-Myers Squibb & Chubb

Todays Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Bristol-Myers Squibb Company (BMY)…

Beat the S&P 500 With This Cash-Gushing Dividend Stock

Investors seeking relief from stock market volatility should take a closer look at Bristol Myers Squibb (NYSE: BMY). At the…

3 Deeply Discounted Dividend Stocks to Buy Today

Want to buy a good dividend stock and secure a great price in the process? I have a list of…

Why Pfizer Is My Largest Healthcare Position

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the…

Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts

Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.…

2 High-Yield Dividend Stocks That Are Bargain Buys Right Now

Healthcare is a defensive sector that is more resilient to economic downturns than most others. Thats one of several reasons…

Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note

Bristol Myers Squibb (BMY) reachead $60.08 at the closing of the latest trading day, reflecting a +0.3% change compared to…

Bristol-Myers Squibb: Why Im Still Bullish

…

5 Reasons the Schwab U.S. Dividend Equity ETF Is a Long-Term Buy for 2030 and Beyond

Lets say you have some money in your pocket you want to invest, but youre not sure where to put…

European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy By Investing.com

European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy…

Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts

Bristol Myers Squibb (BMY) closed at $60.28 in the latest trading session, marking a +0.79% move from the prior day.…

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be…

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

Bristol Myers Squibb (BMY) concluded the recent trading session at $60.18, signifying a +0.6% move from its prior days close.…

Bristol-Myers Squibb Company (BMY) Presents at 45th Annual TD Cowen Health Care Conference (Transcript)

…

Evotec massiv unter Druck: Gute News verpuffen – Aktie mit neuem Verkaufssignal

Lange Zeit war es ruhig bei Evotec. Heute hat der Hamburger Wirkstoffforscher aber positive News aus der langjährigen Neurologie-Partnerschaft mit…

Evotec massiv unter Druck: Gute News verpuffen – Aktie mit neuem Verkaufssignal

Lange Zeit war es ruhig bei Evotec. Heute hat der Hamburger Wirkstoffforscher aber positive News aus der langjährigen Neurologie-Partnerschaft mit…

EQS-News: Evotec gibt wichtige Fortschritte in der Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt (deutsch)

Evotec gibt wichtige Fortschritte in der Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt^EQS-News: Evotec SE / Schlagwort(e): SonstigesEvotec gibt wichtige Fortschritte…

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Bristol Myers Squibb (BMY) concluded the recent trading session at $59.62, signifying a +1.39% move from its prior days close.…

3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade

There are many ways to make money on Wall Street, but some methods are a lot more reliable than others.…

Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week

…

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

…

This Company Just Initiated a Quarterly Dividend: Time to Buy?

Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The companys results were…

Want Decades of Passive Income? Buy This ETF and Hold It Forever.

Who doesnt want passive income? Even Warren Buffett has extolled it, reportedly saying, "If you dont find a way to…

Better High-Yield Dividend Stock: Pfizer vs. Merck

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical…

Is Now a Good Time to Buy the Dip on Pfizer?

The past three years have been difficult for Pfizer (NYSE: PFE). The pharmaceutical giants financial results worsened substantially as its…

Personalized Cell Therapy Market: Growing at a CAGR of 25% From 2024-2032 | Pfizer, CARsgen Therapeutics, Mesoblast Ltd

Bristol Myers Squibbs FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, tackling unmet cancer needs.…

Worried About a Stock Market Crash? Park Your Money in These 2 High-Yielding ETFs for Safety.

Investing in the stock market may not seem like a great idea these days given how expensive many stocks are…

Bristol Myers Squibb (BMY) Q4 2024 Earnings Call Transcript

BMY earnings call for the period ending December 31, 2024.…

Bristol Myers Squibb Tops Q4 Estimates

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.…

Bristol-Myers Squibb Aktie: Prognose drückt auf das Gemüt der Anleger

Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Bristol Myers Squibb: Prognose enttäuscht – Aktie sackt ab

Der amerikanische Biopharma-Riese Bristol Myers Squibb hat die Erwartungen des Marktes im Hinblick auf das vergangene vierte Geschäftsquartal übertroffen. Dennoch…

Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance

The company also issued a 2025 guidance that fell short of expectations, as some of the companys older drugs face…